Regístrese
Buscar en
Revista Española de Anestesiología y Reanimación (English Edition)
Toda la web
Inicio Revista Española de Anestesiología y Reanimación (English Edition) Emerging therapies in clinical development and new contributions for neuropathic...
Journal Information
Vol. 66. Issue 6.
Pages 324-334 (June - July 2019)
Share
Share
Download PDF
More article options
ePub
Visits
2
Vol. 66. Issue 6.
Pages 324-334 (June - July 2019)
Continuing education
DOI: 10.1016/j.redare.2019.02.004
Emerging therapies in clinical development and new contributions for neuropathic pain
Terapias emergentes en desarrollo clínico y nuevas aportaciones en dolor neuropático
Visits
2
A. Alcántara Monteroa,
Corresponding author
a.alcantara.montero@hotmail.com

Corresponding author.
, C.I. Sánchez Carnererob, C. Goicoechea Garcíac
a Centro de Salud Manuel Encinas, Consultorio de Malpartida de Cáceres, Cáceres, Spain
b Complejo Hospitalario Universitario de Cáceres, Hospital San Pedro de Alcántara, Cáceres, Spain
c Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Madrid, Spain
This item has received
2
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Summary of recommendations for the pharmacological treatment of neuropathic pain (adapted citations 5–8).
Table 2. Main pharmacokinetic parameters of gabapentinoids.
Table 3. Summary of RCTs performed in neuropathic pain with the drugs included in this review.
Show moreShow less
Abstract

Neuropathic pain is very challenging to manage because of the heterogeneity of aetiologies, symptoms, and underlying mechanisms. Conventional oral therapies have been limited by negative factors such as systemic side effects, drug–drug interactions, slow onset of action, the need for titration, multiple daily dosing, as well as the potential risk of addiction, dependence, withdrawal symptoms, and abuse. Therefore new therapeutic perspectives are justified. New drugs that act on different therapeutic targets are currently in preclinical development or in their first phases of clinical development. In this review, focus will be directed specifically on new pharmacological treatments for neuropathic pain for which clinical data are already available, including older and known drugs with new data on their anti-neuropathic activity.

Keywords:
BIIB074
Neuropathic pain
EMA401
Fulranumab
Mirogabalin
Botulinum toxin type A
Resumen

El dolor neuropático es difícil de tratar debido a la heterogeneidad de causas, síntomas y mecanismos subyacentes. Los tratamientos orales convencionales se han visto limitados por factores negativos, como efectos secundarios sistémicos, interacciones farmacológicas, inicio de acción lento, necesidad de ajuste de la dosis, administración de múltiples dosis diarias, y posible riesgo de adicción, dependencia, síntomas de abstinencia y uso excesivo. Por tanto, se justifican nuevas perspectivas terapéuticas. Actualmente, se encuentran en desarrollo preclínico o en sus primeras fases de desarrollo clínico nuevos fármacos que actúan sobre diferentes dianas terapéuticas. En esta revisión nos centraremos expresamente en nuevos tratamientos farmacológicos para el dolor neuropático para los cuales ya se dispone de datos clínicos, incluyendo fármacos más antiguos y conocidos con nuevos datos sobre su actividad antineuropática.

Palabras clave:
BIIB074
Dolor neuropático
EMA401
Fulranumab
Mirogabalina
Toxina botulínica tipo A

Article

These are the options to access the full texts of the publication Revista Española de Anestesiología y Reanimación (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Anestesiología y Reanimación (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.